

Merck & Co., Inc.
U.S. Human Health
P.O. Box 1000
North Wales, PA 19454-1099
Tel: 800 672 6372
Fax: 800 637 2568

February 24, 2012

Kenneth C Anderson, M.D.
Dana-Farber Cancer Institute
450 Brookline Avenue, Room M557
Boston, MA 02215-5450



Dear Dr. Anderson:

This is in response to your recent inquiry regarding ZOLINZA (vorinostat). Your inquiry concerned receiving all published literature on the use of ZOLINZA in patients with multiple myeloma.

The following information is provided as a professional service in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and/or data that you requested. Merck does not recommend the use of its products in any manner other than as described in the prescribing information. Enclosed for your convenience is prescribing information for ZOLINZA.

If you require further information or need to report suspected adverse reactions, please contact the Merck National Service Center at 1-800-672-6372.

Sincerely,

Candace Ritchie

Candace Ritchie, PhD
Senior Product Scientific Specialist
Merck Global Medical Information

Enclosures:
ZOLINZA Prescribing Information
Published Literature

Case Number US12-008670

2/28/12
Dorothy: They had asked me about
considering ZOLINZA by NCCN panel
so I asked them to forward relevant
information. Can we consider as a
panel please
Many Thanks!
Ken